DT-Web

DB00909 - Zonisamide


Identification
Name Zonisamide
Accession Number DB00909 (APRD00004)
Type small molecule
Description Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 212.226
Groups approved
Monoisotopic Weight 212.025562822
Pharmacology
Indication For use as adjunctive treatment of partial seizures in adults with epilepsy.
Mechanism of action Zonisamide binds to sodium channels and voltage sensitive calcium channels, which suppresses neuronal depolarization and hypersynchronization. Zonisamide also inhibits carbonic anhydrase to a weaker extent, but such an effect is not thought to contribute substantially to the drug's anticonvulsant activity.
Absorption Variable, yet relatively rapid rate of absorption with a time to peak concentration of 2.8-3.9 hours. Food has no effect on the bioavailability of zonisamide.
Protein binding 40% (at concentrations of 1.0-7.0 µg/mL)
Biotransformation Primarily hepatic through cytochrome P450 isoenzyme 3A4 (CYP3A4). Undergoes acetylation and reduction, forming N-acetyl zonisamide, and the open-ring metabolite 2–sulfamoylacetyl phenol, respectively.
Route of elimination Zonisamide is excreted primarily in urine as parent drug and as the glucuronide of a metabolite.
Toxicity Symptoms of overdose include diminished breathing, loss of consciousness, low blood pressure, and slow heartbeat.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Amprenavir Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if amprenavir is initiated, discontinued or dose changed.
Atazanavir Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if atazanavir is initiated, discontinued or dose changed.
Brinzolamide As both brinzolamide and zonisamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible.
Clarithromycin Clarithromcyin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if clarithromycin is initiated, discontinued or dose changed.
Conivaptan Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if conivaptan is initiated, discontinued or dose changed.
Darunavir Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if darunavir is initiated, discontinued or dose changed.
Delavirdine Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if delavirdine is initiated, discontinued or dose changed.
Fosamprenavir Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if fosamprenavir is initiated, discontinued or dose changed.
Imatinib Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if imatinib is initiated, discontinued or dose changed.
Indinavir Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if indinavir is initiated, discontinued or dose changed.
Isoniazid Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if isoniazid is initiated, discontinued or dose changed.
Itraconazole Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if itraconazole is initiated, discontinued or dose changed.
Ketoconazole Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed.
Lopinavir Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if lopinavir is initiated, discontinued or dose changed.
Mefloquine Mefloquine may decrease the serum concentration and therapeutic effect of zonisamide. Concomitant therapy is contraindicated in patients with history of convulsions.
Methotrimeprazine Additive CNS depressant effects. Reduce zonisamide dose by half upon initiation of methotrimeprazine. Zonisamide dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.
Nefazodone Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nefazodone is initiated, discontinued or dose changed.
Nelfinavir Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nelfinavir is initiated, discontinued or dose changed.
Nicardipine Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nicardipine is initiated, discontinued or dose changed.
Posaconazole Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if posaconazole is initiated, discontinued or dose changed.
Quinidine Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if quinidine is initiated, discontinued or dose changed.
Ritonavir Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ritonavir is initiated, discontinued or dose changed.
Saquinavir Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if saquinavir is initiated, discontinued or dose changed.
Telithromycin Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if telithromycin is initiated, discontinued or dose changed.
Triprolidine The CNS depressants, Triprolidine and Zonisamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if voriconazole is initiated, discontinued or dose changed.
Food Interactions Not Available

Targets


Sodium channel protein type 1 subunit alpha
Name Sodium channel protein type 1 subunit alpha
Gene Name SCN1A
Pharmacological action yes
Actions inhibitor
References
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
DTHybrid score 0.8402
Sodium channel protein type 2 subunit alpha
Name Sodium channel protein type 2 subunit alpha
Gene Name SCN2A
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.6181
Sodium channel protein type 3 subunit alpha
Name Sodium channel protein type 3 subunit alpha
Gene Name SCN3A
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.8986
Sodium channel protein type 4 subunit alpha
Name Sodium channel protein type 4 subunit alpha
Gene Name SCN4A
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.5563
Sodium channel protein type 5 subunit alpha
Name Sodium channel protein type 5 subunit alpha
Gene Name SCN5A
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.838
Sodium channel protein type 9 subunit alpha
Name Sodium channel protein type 9 subunit alpha
Gene Name SCN9A
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.8565
Sodium channel protein type 11 subunit alpha
Name Sodium channel protein type 11 subunit alpha
Gene Name SCN11A
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.5345
Sodium channel subunit beta-1
Name Sodium channel subunit beta-1
Gene Name SCN1B
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.6288
Sodium channel subunit beta-2
Name Sodium channel subunit beta-2
Gene Name SCN2B
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.6284
Sodium channel subunit beta-3
Name Sodium channel subunit beta-3
Gene Name SCN3B
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.6288
Sodium channel subunit beta-4
Name Sodium channel subunit beta-4
Gene Name SCN4B
Pharmacological action yes
Actions inhibitor
References
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
DTHybrid score 0.6285
Voltage-dependent T-type calcium channel subunit alpha-1G
Name Voltage-dependent T-type calcium channel subunit alpha-1G
Gene Name CACNA1G
Pharmacological action yes
Actions inhibitor
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. - Pubmed
  • Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
DTHybrid score 0.5906
Voltage-dependent T-type calcium channel subunit alpha-1H
Name Voltage-dependent T-type calcium channel subunit alpha-1H
Gene Name CACNA1H
Pharmacological action yes
Actions inhibitor
References
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. - Pubmed
  • Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
DTHybrid score 0.4696
Voltage-dependent T-type calcium channel subunit alpha-1I
Name Voltage-dependent T-type calcium channel subunit alpha-1I
Gene Name CACNA1I
Pharmacological action yes
Actions inhibitor
References
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. - Pubmed
  • Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. - Pubmed
  • Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases] Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. - Pubmed
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. - Pubmed
  • Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. - Pubmed
  • Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
DTHybrid score 0.5104
Carbonic anhydrase 1
Name Carbonic anhydrase 1
Gene Name CA1
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Shank RP, Smith-Swintosky VL, Maryanoff BE: Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6. - Pubmed
  • Masuda Y, Karasawa T: Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung. 1993 Apr;43(4):416-8. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 1.2799
Carbonic anhydrase 2
Name Carbonic anhydrase 2
Gene Name CA2
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Shank RP, Smith-Swintosky VL, Maryanoff BE: Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6. - Pubmed
  • De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. - Pubmed
  • Masuda Y, Karasawa T: Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung. 1993 Apr;43(4):416-8. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 2.3177
Carbonic anhydrase 3
Name Carbonic anhydrase 3
Gene Name CA3
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.7085
Carbonic anhydrase 4
Name Carbonic anhydrase 4
Gene Name CA4
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 1.138
Carbonic anhydrase 5A, mitochondrial
Name Carbonic anhydrase 5A, mitochondrial
Gene Name CA5A
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.8552
Carbonic anhydrase 5B, mitochondrial
Name Carbonic anhydrase 5B, mitochondrial
Gene Name CA5B
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.6499
Carbonic anhydrase 6
Name Carbonic anhydrase 6
Gene Name CA6
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score Not Available
Carbonic anhydrase 7
Name Carbonic anhydrase 7
Gene Name CA7
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.7974
Carbonic anhydrase-related protein
Name Carbonic anhydrase-related protein
Gene Name CA8
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.6287
Carbonic anhydrase 9
Name Carbonic anhydrase 9
Gene Name CA9
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.8063
Carbonic anhydrase-related protein 10
Name Carbonic anhydrase-related protein 10
Gene Name CA10
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.6287
Carbonic anhydrase-related protein 11
Name Carbonic anhydrase-related protein 11
Gene Name CA11
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.6289
Carbonic anhydrase 12
Name Carbonic anhydrase 12
Gene Name CA12
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.8066
Carbonic anhydrase 13
Name Carbonic anhydrase 13
Gene Name CA13
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 1.3211
Carbonic anhydrase 14
Name Carbonic anhydrase 14
Gene Name CA14
Pharmacological action unknown
Actions inhibitor
References
  • De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. - Pubmed
  • Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
  • Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. - Pubmed
  • Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. - Pubmed
DTHybrid score 0.7534
Amine oxidase [flavin-containing] B
Name Amine oxidase [flavin-containing] B
Gene Name MAOB
Pharmacological action unknown
Actions inhibitor
References
  • Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. Epub 2009 Dec 4. - Pubmed
  • Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. - Pubmed
  • Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res. 2001 Dec;41(4):397-9. - Pubmed
  • Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193-205. - Pubmed
  • Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. - Pubmed
  • Okada M: [Effects of carbamazepine and zonisamide on dopaminergic system in rat striatum and hippocampus] Nihon Shinkei Seishin Yakurigaku Zasshi. 1994 Oct;14(5):337-54. - Pubmed
  • Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. - Pubmed
DTHybrid score 1.1854
Amine oxidase [flavin-containing] A
Name Amine oxidase [flavin-containing] A
Gene Name MAOA
Pharmacological action unknown
Actions inhibitor
References
  • Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193-205. - Pubmed
  • Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. - Pubmed
DTHybrid score 0.7827

Enzymes


Cytochrome P450 3A4
Name Cytochrome P450 3A4
Gene Name CYP3A4
Actions substrate
References
  • Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M: Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol. 1993 Jul;44(1):216-21. - Pubmed
  • Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. - Pubmed
  • Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. - Pubmed
  • Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M: Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83. - Pubmed
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.8024
Aldehyde oxidase
Name Aldehyde oxidase
Gene Name AOX1
Actions substrate
References
  • -
  • Sugihara K, Kitamura S, Tatsumi K: Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Dispos. 1996 Feb;24(2):199-202. - Pubmed
  • Kitamura S, Ohashi KNK, Sugihara K, Hosokawa R, Akagawa Y, Ohta S: Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver. Biol Pharm Bull. 2001 Jul;24(7):856-9. - Pubmed
DTHybrid score 0.5016
Cytochrome P450 2C19
Name Cytochrome P450 2C19
Gene Name CYP2C19
Actions inhibitor
References
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.535

Predictions


Id Partner name Gene Name Score
4757 Cytochrome P450 2C9 CYP2C9 0.3922
4119 Cytochrome P450 2D6 CYP2D6 0.3742
198 Sodium channel protein type 10 subunit alpha SCN10A 0.2812
1729 Solute carrier family 22 member 6 SLC22A6 0.2783
466 Solute carrier family 12 member 3 SLC12A3 0.275
4200 Cytochrome P450 1A2 CYP1A2 0.2622
6013 Cytochrome P450 2E1 CYP2E1 0.2485
1588 Multidrug resistance protein 1 ABCB1 0.2102
4924 Cytochrome P450 2C8 CYP2C8 0.2082
6030 Cytochrome P450 2B6 CYP2B6 0.2076
6024 Cytochrome P450 1A1 CYP1A1 0.1902
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.1813
4118 Cytochrome P450 3A5 CYP3A5 0.1804
1025 Aquaporin-1 AQP1 0.1689
6107 Cytochrome P450 3A7 CYP3A7 0.1545
558 Solute carrier family 12 member 1 SLC12A1 0.1491
997 Protein kinase C beta type PRKCB 0.13
5718 Cytochrome P450 2A6 CYP2A6 0.1232
634 Squalene monooxygenase SQLE 0.1201
7196 Squalene monooxygenase ERG1 0.1201
2408 Tyrosine-protein kinase SYK SYK 0.1201
1970 Protein kinase C alpha type PRKCA 0.1177
824 Sodium-dependent serotonin transporter SLC6A4 0.1087
587 Serum albumin ALB 0.1064
806 Sodium/potassium-transporting ATPase alpha-1 chain ATP1A1 0.1054
4115 Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D 0.1042
4111 Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S 0.1028
478 Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C 0.1005
713 Sodium-dependent dopamine transporter SLC6A3 0.0935
2236 Casein kinase II subunit alpha CSNK2A1 0.0928
1024 Solute carrier family 22 member 11 SLC22A11 0.0867
6263 cAMP-dependent protein kinase catalytic subunit alpha PRKACA 0.0813
6106 Cytochrome P450 2C18 CYP2C18 0.0799
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0786
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0769
4110 Voltage-dependent L-type calcium channel subunit beta-2 CACNB2 0.0762
4113 Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F 0.0761
465 Calmodulin CALM1 0.0746
6176 UDP-glucuronosyltransferase 1-3 UGT1A3 0.07
1405 Thiopurine S-methyltransferase TPMT 0.0654
492 Histamine H1 receptor HRH1 0.0648
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.0579
872 Gamma-aminobutyric-acid receptor subunit alpha-1 GABRA1 0.0551
1181 Alpha-1-acid glycoprotein 1 ORM1 0.055
318 Alpha-2A adrenergic receptor ADRA2A 0.0545
253 Sodium/potassium-transporting ATPase gamma chain FXYD2 0.052
3947 Xanthine dehydrogenase/oxidase XDH 0.0507
6144 Solute carrier family 22 member 2 SLC22A2 0.0501
2178 Metabotropic glutamate receptor 5 GRM5 0.0496
20 Prostaglandin G/H synthase 1 PTGS1 0.0454
3811 Cytochrome P450 19A1 CYP19A1 0.0454
4114 Voltage-dependent L-type calcium channel subunit beta-3 CACNB3 0.0453
4112 Voltage-dependent L-type calcium channel subunit beta-4 CACNB4 0.0453
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0445
382 Glutamate receptor, ionotropic kainate 1 GRIK1 0.0443
4784 Beta-mannosidase manB 0.0432
6695 Beta-mannosidase BT_0458 0.0432
6142 Solute carrier family 22 member 8 SLC22A8 0.0416
762 Voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 0.0416
333 Voltage-dependent L-type calcium channel subunit beta-1 CACNB1 0.0407
118 Organic cation/carnitine transporter 2 SLC22A5 0.0396
1757 Myeloperoxidase MPO 0.0396
831 D(2) dopamine receptor DRD2 0.0395
1735 Canalicular multispecific organic anion transporter 1 ABCC2 0.0393
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0389
629 Alpha-2B adrenergic receptor ADRA2B 0.0382
378 Alpha-2C adrenergic receptor ADRA2C 0.0379
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0379
556 Alpha-1A adrenergic receptor ADRA1A 0.0378
6031 Cytochrome P450 3A43 CYP3A43 0.0362
805 Cytochrome P450 11B1, mitochondrial CYP11B1 0.0362
131 Synaptic vesicular amine transporter SLC18A2 0.0355
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0353
6145 Solute carrier family 22 member 1 SLC22A1 0.035
2353 Apolipoprotein(a) LPA 0.0343
617 Muscarinic acetylcholine receptor M2 CHRM2 0.0338
2297 Genome polyprotein Not Available 0.0337
2322 Genome polyprotein Not Available 0.0337
2694 Genome polyprotein Not Available 0.0337
2719 Genome polyprotein Not Available 0.0337
2860 Genome polyprotein Not Available 0.0337
2928 Genome polyprotein Not Available 0.0337
3160 Genome polyprotein Not Available 0.0337
3260 Genome polyprotein Not Available 0.0337
4783 Genome polyprotein Not Available 0.0337
5726 Genome polyprotein Not Available 0.0337
5779 Genome polyprotein Not Available 0.0337
5867 Genome polyprotein Not Available 0.0337
6253 Genome polyprotein Not Available 0.0337
6301 Genome polyprotein Not Available 0.0337
6380 Genome polyprotein Not Available 0.0337
6381 Genome polyprotein Not Available 0.0337
6437 Genome polyprotein Not Available 0.0337
6520 Genome polyprotein Not Available 0.0337
6521 Genome polyprotein Not Available 0.0337
6652 Genome polyprotein Not Available 0.0337
6734 Genome polyprotein Not Available 0.0337
6735 Genome polyprotein Not Available 0.0337
6736 Genome polyprotein Not Available 0.0337
6737 Genome polyprotein Not Available 0.0337
6738 Genome polyprotein Not Available 0.0337
6739 Genome polyprotein Not Available 0.0337
6744 Genome polyprotein Not Available 0.0337
6748 Genome polyprotein Not Available 0.0337
6894 Genome polyprotein Not Available 0.0337
6898 Genome polyprotein Not Available 0.0337
511 5-hydroxytryptamine 1F receptor HTR1F 0.0337
4604 Liver carboxylesterase 1 CES1 0.0334
723 Cytosolic phospholipase A2 PLA2G4A 0.0331
885 5-hydroxytryptamine 1B receptor HTR1B 0.0326
2998 Sialic acid-binding Ig-like lectin 7 SIGLEC7 0.0325
725 5-hydroxytryptamine 1D receptor HTR1D 0.0323
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0323
3923 Cholinesterase BCHE 0.0322
4100 Gamma-aminobutyric-acid receptor subunit beta-2 GABRB2 0.0322
1898 Cytochrome P450 1B1 CYP1B1 0.032
4099 Gamma-aminobutyric-acid receptor subunit beta-3 GABRB3 0.032
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0316
193 Beta-1 adrenergic receptor ADRB1 0.0315
6181 UDP-glucuronosyltransferase 1-8 UGT1A8 0.031
234 Plasminogen PLG 0.0306
6032 PROBABLE FATTY ACID SYNTHASE FAS (FATTY ACID SYNTHETASE) fas 0.0304
3437 Eosinophil lysophospholipase CLC 0.0303
3810 Catechol O-methyltransferase COMT 0.0298
4787 Envelope glycoprotein gp160 env 0.0295
4820 Envelope glycoprotein gp160 env 0.0295
5727 Envelope glycoprotein gp160 env 0.0295
2164 Multidrug resistance-associated protein 4 ABCC4 0.029
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0288
3937 Fatty-acid amide hydrolase FAAH 0.0284
862 Multidrug resistance-associated protein 1 ABCC1 0.0281
6143 Solute carrier family 22 member 7 SLC22A7 0.0276
1792 Tissue-type plasminogen activator PLAT 0.0273
3480 Mannan endo-1,4-beta-mannosidase manA 0.0262
338 DNA polymerase UL30 0.0258
379 DNA polymerase UL54 0.0258
697 DNA polymerase ORF28 0.0258
2482 DNA polymerase 43 0.0258
4104 DNA polymerase BALF5 0.0258
320 5-hydroxytryptamine 1A receptor HTR1A 0.0254
146 Androgen receptor AR 0.0246
6158 Solute carrier organic anion transporter family member 1C1 SLCO1C1 0.0241
6023 Cytochrome P450 11B2, mitochondrial CYP11B2 0.024
502 5-hydroxytryptamine 2A receptor HTR2A 0.0238
2864 Penton protein PIII 0.0236
392 Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A 0.0232
6047 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A PDE1A 0.0228
423 Gamma-aminobutyric-acid receptor subunit alpha-2 GABRA2 0.0224
844 Epidermal growth factor receptor EGFR 0.0223
64 Neuraminidase NA 0.022
641 Neuraminidase NA 0.022
2676 Neuraminidase NA 0.022
3026 Neuraminidase NA 0.022
3519 Neuraminidase NA 0.022
6007 Neuraminidase NA 0.022
2207 Rhodopsin RHO 0.0217
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0216
136 Estrogen receptor ESR1 0.0216
833 Organic cation/carnitine transporter 1 SLC22A4 0.0212
5692 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B PDE1B 0.021
6147 Solute carrier family 22 member 3 SLC22A3 0.0208
23 D(1A) dopamine receptor DRD1 0.0207
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0207
632 Alpha-1B adrenergic receptor ADRA1B 0.0207
5841 Insulin-like growth factor IB IGF1 0.0206
3623 Divalent-cation tolerance protein cutA cutA 0.0206
1709 Canalicular multispecific organic anion transporter 2 ABCC3 0.0198
789 Alpha-1D adrenergic receptor ADRA1D 0.0196
766 Beta-2 adrenergic receptor ADRB2 0.0191
310 Solute carrier family 12 member 2 SLC12A2 0.0189
4785 Ig gamma-1 chain C region IGHG1 0.0187
811 Translocator protein TSPO 0.0184
290 Prostaglandin G/H synthase 2 PTGS2 0.018
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.018
776 Bile salt export pump ABCB11 0.0177
871 Glucocorticoid receptor NR3C1 0.0176
741 Potassium voltage-gated channel subfamily KQT member 1 KCNQ1 0.0161
260 Cytochrome P450 51 ERG11 0.0161
761 Cytochrome P450 51 ERG11 0.0161
3163 Cytochrome P450 51 cyp51 0.0161
273 Apoptosis regulator Bcl-2 BCL2 0.016
731 HIV-1 protease HIV-1 protease 0.0157
580 Gamma-aminobutyric-acid receptor subunit alpha-3 GABRA3 0.0156
172 Potassium channel subfamily K member 1 KCNK1 0.015
6148 Multidrug resistance-associated protein 7 ABCC10 0.0147
523 Gamma-aminobutyric-acid receptor subunit alpha-5 GABRA5 0.0146
3917 Methylenetetrahydrofolate reductase MTHFR 0.0141
51 Muscarinic acetylcholine receptor M3 CHRM3 0.0141
3970 Voltage-dependent N-type calcium channel subunit alpha-1B CACNA1B 0.0138
750 Voltage-dependent calcium channel gamma-1 subunit CACNG1 0.0137
3226 UPF0234 protein HI1034 HI_1034 0.0135
3384 Macrophage migration inhibitory factor MIF 0.0132
869 Estrogen receptor beta ESR2 0.0132
3426 Glutamine synthetase glnA 0.0129
3987 Glutamine synthetase GLUL 0.0129
389 Amiloride-sensitive cation channel 2, neuronal ACCN2 0.0126
6220 Aryl hydrocarbon receptor AHR 0.0124
6136 Multidrug resistance-associated protein 5 ABCC5 0.0123
530 Gamma-aminobutyric-acid receptor subunit alpha-4 GABRA4 0.0122
841 Gamma-aminobutyric-acid receptor subunit alpha-6 GABRA6 0.0121
590 5-hydroxytryptamine 2C receptor HTR2C 0.0121
4162 Potassium voltage-gated channel subfamily KQT member 3 KCNQ3 0.012
385 Potassium-transporting ATPase alpha chain 1 ATP4A 0.0119
1086 Potassium voltage-gated channel subfamily KQT member 2 KCNQ2 0.0117
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.0115
1656 CYP2B protein CYP2B 0.0115
6093 Gamma-aminobutyric acid receptor subunit delta GABRD 0.0112
6087 Gamma-aminobutyric acid receptor subunit gamma-1 GABRG1 0.0112
6089 Gamma-aminobutyric acid receptor subunit epsilon GABRE 0.0112
2222 Equilibrative nucleoside transporter 1 SLC29A1 0.0112
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.0109
6086 Gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 0.0109
1483 Membrane copper amine oxidase AOC3 0.0109
6088 Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3 0.0109
6090 Gamma-aminobutyric acid receptor subunit pi GABRP 0.0109
6092 Gamma-aminobutyric acid receptor subunit rho-2 GABRR2 0.0109
6115 Gamma-aminobutyric acid receptor subunit rho-3 GABRR3 0.0109
3105 M-phase inducer phosphatase 2 CDC25B 0.0108
4098 Gamma-aminobutyric-acid receptor subunit beta-1 GABRB1 0.0108
6171 Solute carrier family 28 member 3 SLC28A3 0.0107
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0107
142 Gamma-aminobutyric-acid receptor subunit rho-1 GABRR1 0.0107
33 Cystine/glutamate transporter SLC7A11 0.0107
233 Potassium channel subfamily K member 2 KCNK2 0.0107
87 Hypoxanthine-guanine phosphoribosyltransferase HPRT1 0.0105
5698 Riboflavin synthase alpha chain ribE 0.0105
921 Glutamate receptor 2 GRIA2 0.0105
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0104
373 Transthyretin TTR 0.0104
408 Riboflavin kinase RFK 0.0101
847 Mu-type opioid receptor OPRM1 0.01
275 Arachidonate 5-lipoxygenase ALOX5 0.01
638 D(3) dopamine receptor DRD3 0.0097
787 Vitamin K epoxide reductase complex subunit 1 VKORC1 0.0095
3913 Glutamic acid decarboxylase GAD65 0.0094
6091 Gamma-aminobutyric acid receptor subunit theta GABRQ 0.0093
6014 Cytochrome P450 2A13 CYP2A13 0.0092
6048 Troponin C, skeletal muscle TNNC2 0.0092
467 Delta-type opioid receptor OPRD1 0.0089
1517 Beta-3 adrenergic receptor ADRB3 0.0088
2981 Phospholipase A2, membrane associated PLA2G2A 0.0088
468 Cytochrome P450 4A11 CYP4A11 0.0085
341 5-hydroxytryptamine 3 receptor HTR3A 0.0083
274 Muscarinic acetylcholine receptor M5 CHRM5 0.0083
432 D(4) dopamine receptor DRD4 0.0082
654 Flavin reductase BLVRB 0.0081
450 Muscarinic acetylcholine receptor M4 CHRM4 0.0081
1636 Trace amine-associated receptor 1 TAAR1 0.0081
232 Corticosteroid-binding globulin SERPINA6 0.008
737 Mineralocorticoid receptor NR3C2 0.0079
400 Coagulation factor IX F9 0.0079
5461 Coagulation factor IX F9 0.0079
436 5-hydroxytryptamine 2B receptor HTR2B 0.0079
442 Envelope glycoprotein gp41 0.0078
4859 Envelope glycoprotein env 0.0078
735 Alanine aminotransferase 1 GPT 0.0077
3904 Alanine aminotransferase 2 GPT2 0.0077
243 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 0.0076
614 Progesterone receptor PGR 0.0076
696 Kappa-type opioid receptor OPRK1 0.0076
6098 Potassium voltage-gated channel subfamily D member 2 KCND2 0.0075
6099 Potassium voltage-gated channel subfamily D member 3 KCND3 0.0075
122 P2Y purinoceptor 12 P2RY12 0.0074
4081 Vitamin K epoxide reductase complex subunit 1-like protein 1 VKORC1L1 0.0073
604 Vitamin K-dependent protein Z PROZ 0.0073
204 cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A 0.0072
818 50S ribosomal protein L10 rplJ 0.0071
280 4-aminobutyrate aminotransferase, mitochondrial ABAT 0.0071
6164 POU domain, class 5, transcription factor 1 POU5F1 0.0069
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.0068
6182 Cytochrome P450 2J2 CYP2J2 0.0068
3627 UPF0190 protein yedY yedY 0.0067
4095 Neuronal acetylcholine receptor subunit alpha-7 CHRNA7 0.0067
947 Neuronal acetylcholine receptor subunit alpha-4 CHRNA4 0.0067
1392 Catenin beta-1 CTNNB1 0.0067
3352 Structural polyprotein Not Available 0.0067
3628 Structural polyprotein Not Available 0.0067
4892 Structural polyprotein Not Available 0.0067
163 D(1B) dopamine receptor DRD5 0.0067
422 Vitamin K-dependent protein C PROC 0.0066
1245 Vitamin K-dependent protein S PROS1 0.0066
230 ATP-binding cassette transporter sub-family C member 8 ABCC8 0.0065
817 DNA topoisomerase 2-alpha TOP2A 0.0065
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.0064
238 Peroxisome proliferator-activated receptor gamma PPARG 0.0064
606 Cytochrome P450 27, mitochondrial CYP27A1 0.0064
474 Acetylcholinesterase ACHE 0.0064
153 Dopamine beta-hydroxylase DBH 0.0062
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0062
756 Sex hormone-binding globulin SHBG 0.0061
1064 DNA (cytosine-5)-methyltransferase 1 DNMT1 0.0061
464 Glutamate [NMDA] receptor subunit epsilon-2 GRIN2B 0.006
4148 Serine/threonine-protein kinase mTOR MTOR 0.0059
694 Matrix protein 2 M 0.0059
448 Vitamin K-dependent gamma-carboxylase GGCX 0.0059
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0058
124 Histamine H2 receptor HRH2 0.0058
6045 Voltage-dependent calcium channel subunit alpha-2/delta-3 CACNA2D3 0.0058
631 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR 0.0056
3387 3-hydroxy-3-methylglutaryl-coenzyme A reductase mvaA 0.0056
6040 6-phosphogluconate dehydrogenase, decarboxylating PGD 0.0056
239 Coagulation factor X F10 0.0055
161 Tubulin beta chain TUBB 0.0054
312 Tubulin beta chain TUB2 0.0054
798 Osteocalcin BGLAP 0.0053
49 Endothelin B receptor EDNRB 0.0052
1284 Nuclear receptor subfamily 1 group I member 2 NR1I2 0.0052
365 Dihydrofolate reductase DHFR 0.0051
2381 Dihydrofolate reductase DFR1 0.0051
2833 Dihydrofolate reductase Not Available 0.0051
2931 Dihydrofolate reductase folA 0.0051
3544 Dihydrofolate reductase folA 0.0051
3682 Dihydrofolate reductase folA 0.0051
6642 Dihydrofolate reductase folA 0.0051
6756 Dihydrofolate reductase dfrA 0.0051
2157 NAD(P)H dehydrogenase [quinone] 1 NQO1 0.0051
1974 Oligopeptide transporter, kidney isoform SLC15A2 0.005
3876 Aromatic-L-amino-acid decarboxylase DDC 0.005
837 Glutamate [NMDA] receptor subunit epsilon-1 GRIN2A 0.005
578 Endothelin-1 receptor EDNRA 0.0049
777 Tumor necrosis factor TNF 0.0049
6150 Solute carrier organic anion transporter family member 4C1 SLCO4C1 0.0049
6078 Neuronal acetylcholine receptor subunit beta-4 CHRNB4 0.0049
5818 Folate receptor alpha FOLR1 0.0049
948 Neuronal acetylcholine receptor subunit beta-2 CHRNB2 0.0049
6080 Neuronal acetylcholine receptor subunit alpha-5 CHRNA5 0.0049
6082 Neuronal acetylcholine receptor subunit beta-3 CHRNB3 0.0049
6079 Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 0.0048
68 Cannabinoid receptor 1 CNR1 0.0048
6046 Voltage-gated calcium channel beta 1 subunit splice variant CavB1d CACNB1 0.0048
369 Coagulation factor VII F7 0.0048
4120 NADPH--cytochrome P450 reductase POR 0.0046
4097 Neuronal acetylcholine receptor subunit alpha-9 CHRNA9 0.0046
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0046
6141 Sodium/bile acid cotransporter SLC10A1 0.0045
6081 Neuronal acetylcholine receptor subunit alpha-6 CHRNA6 0.0045
80 Peroxisome proliferator-activated receptor alpha PPARA 0.0045
567 Receptor tyrosine-protein kinase erbB-2 ERBB2 0.0044
70 Type-1 angiotensin II receptor AGTR1 0.0044
571 Melatonin receptor type 1A MTNR1A 0.0044
362 Melatonin receptor type 1B MTNR1B 0.0044
716 5-hydroxytryptamine 7 receptor HTR7 0.0044
6155 ATP-binding cassette transporter sub-family C member 11 ABCC11 0.0043
952 Dipeptidyl peptidase 4 DPP4 0.0043
2539 Tubulin alpha-1 chain TUBA4A 0.0043
293 Gamma-glutamyl hydrolase GGH 0.0043
856 Vitamin D3 receptor VDR 0.0042
407 Vascular endothelial growth factor receptor 2 KDR 0.0042
6137 Multidrug resistance-associated protein 6 ABCC6 0.0042
6068 Guanylate cyclase soluble subunit alpha-2 GUCY1A2 0.0041
3997 Cytochrome P450 24A1, mitochondrial CYP24A1 0.0041
29 Tubulin beta-1 chain TUBB1 0.004
26 Vascular endothelial growth factor receptor 3 FLT4 0.004
315 Arginase-1 ARG1 0.004
54 Prothrombin F2 0.004
380 Cytochrome P450 17A1 CYP17A1 0.0039
1129 C-C chemokine receptor type 5 CCR5 0.0039
32 Vascular endothelial growth factor receptor 1 FLT1 0.0038
918 Glutamate receptor, ionotropic kainate 2 GRIK2 0.0038
738 Monocarboxylate transporter 1 SLC16A1 0.0038
485 cGMP-inhibited 3',5'-cyclic phosphodiesterase A PDE3A 0.0038
85 Growth hormone receptor GHR 0.0038
1650 Heme carrier protein 1 SLC46A1 0.0037
813 Neuronal acetylcholine receptor subunit alpha-2 CHRNA2 0.0037
276 Sodium- and chloride-dependent GABA transporter 1 SLC6A1 0.0036
773 Folylpolyglutamate synthase, mitochondrial FPGS 0.0036
633 Penicillin-binding proteins 1A/1B pbpA 0.0036
4237 50S ribosomal protein L22 rplV 0.0035
6102 Arylamine N-acetyltransferase 2 NAT2 0.0035
185 Vasopressin V1a receptor AVPR1A 0.0035
939 50S ribosomal protein L3 rplC 0.0035
504 Mast/stem cell growth factor receptor KIT 0.0035
322 Vasopressin V2 receptor AVPR2 0.0034
6043 Putative G-protein coupled receptor 44 GPR44 0.0034
596 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 0.0033
24 Thymidylate synthase TMP1 0.0033
359 Thymidylate synthase TYMS 0.0033
2626 Thymidylate synthase thyA 0.0033
2729 Thymidylate synthase thyA 0.0033
5352 Thymidylate synthase THYA 0.0033
284 DNA-directed RNA polymerase beta chain rpoB 0.0033
5773 DNA-directed RNA polymerase beta chain rpoB 0.0033
814 Ryanodine receptor 1 RYR1 0.0033
427 Substance-P receptor TACR1 0.0033
183 Vascular endothelial growth factor A VEGFA 0.0032
2287 Bifunctional purine biosynthesis protein PURH [Includes: Phosphoribosylaminoimidazolecarboxamide formyltransferase ATIC 0.0032
1010 Cytochrome P450 51A1 CYP51A1 0.0032
140 30S ribosomal protein S9 rpsI 0.0031
6719 30S ribosomal protein S9 rpsI 0.0031
6725 30S ribosomal protein S9 rpsI 0.0031
6160 Solute carrier organic anion transporter family member 3A1 SLCO3A1 0.0031
5300 Antigen peptide transporter 1 TAP1 0.0031
2578 Tubulin beta-3 chain TUBB3 0.003
751 Potassium channel subfamily K member 6 KCNK6 0.003
2285 Streptogramin A acetyltransferase vatD 0.003
228 Beta platelet-derived growth factor receptor PDGFRB 0.003
147 Aldehyde dehydrogenase, mitochondrial ALDH2 0.0029
891 Dihydropteroate synthase folP 0.0029
5359 Dihydropteroate synthase folP 0.0029
7175 Dihydropteroate synthase sulI 0.0029
6177 UDP-glucuronosyltransferase 1-10 UGT1A10 0.0028
4177 Proto-oncogene tyrosine-protein kinase receptor ret RET 0.0028
778 Cysteinyl leukotriene receptor 1 CYSLTR1 0.0028
528 5-hydroxytryptamine 1E receptor HTR1E 0.0028
462 Intermediate conductance calcium-activated potassium channel protein 4 KCNN4 0.0027
4173 Tyrosine-protein kinase JAK2 JAK2 0.0027
6038 Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6H 0.0026
1256 5-hydroxytryptamine 6 receptor HTR6 0.0026
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.0025
17 Proto-oncogene tyrosine-protein kinase ABL1 ABL1 0.0025
768 FK506-binding protein 1A FKBP1A 0.0025
6037 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma PDE6G 0.0025
2268 Cholesterol oxidase choB 0.0025
2822 Cholesterol oxidase choA 0.0025
6152 Solute carrier organic anion transporter family member 2A1 SLCO2A1 0.0024
581 Cytochrome P450 2R1 CYP2R1 0.0024
705 Glutamate receptor 1 GRIA1 0.0024
698 B-Raf proto-oncogene serine/threonine-protein kinase BRAF 0.0024
544 Potassium voltage-gated channel subfamily E member 1 KCNE1 0.0024
6432 Transporter snf 0.0024
6039 Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A PDE11A 0.0024
950 Alpha platelet-derived growth factor receptor PDGFRA 0.0024
364 Corticosteroid 11-beta-dehydrogenase isozyme 1 HSD11B1 0.0024
5852 Type-2 angiotensin II receptor AGTR2 0.0024
178 NADH-cytochrome b5 reductase 3 CYB5R3 0.0024
812 Dihydrolipoyl dehydrogenase, mitochondrial DLD 0.0024
642 3-oxo-5-alpha-steroid 4-dehydrogenase 2 SRD5A2 0.0023
605 Fumarate reductase flavoprotein subunit frdA 0.0023
2709 Fumarate reductase flavoprotein subunit SO_0970 0.0023
3673 Fumarate reductase flavoprotein subunit fccA 0.0023
4912 Fumarate reductase flavoprotein subunit ifcA 0.0023
6549 Fumarate reductase flavoprotein subunit frdA 0.0023
2184 Cystic fibrosis transmembrane conductance regulator CFTR 0.0023
620 Bifunctional dihydrofolate reductase-thymidylate synthase Not Available 0.0023
990 Dual specificity mitogen-activated protein kinase kinase 1 MAP2K1 0.0022
6180 UDP-glucuronosyltransferase 2B4 UGT2B4 0.0022
259 Microsomal triglyceride transfer protein large subunit MTTP 0.0022
2449 Tubulin alpha-3 chain TUBA1A 0.0021
298 Renin REN 0.0021
6506 Stathmin-4 STMN4 0.0021
839 Short-chain specific acyl-CoA dehydrogenase, mitochondrial ACADS 0.0021
40 RAF proto-oncogene serine/threonine-protein kinase RAF1 0.0021
1787 Nuclear factor NF-kappa-B p105 subunit NFKB1 0.0021
823 Fibroblast growth factor receptor 2 FGFR2 0.002
1618 High affinity nerve growth factor receptor NTRK1 0.002
3090 Chitosanase csn 0.002
4149 Nuclear factor NF-kappa-B p100 subunit NFKB2 0.002
4311 tRNA TRDMT1 0.002
4325 tRNA trmD 0.002
4328 tRNA trmD 0.002
518 Peroxidase/catalase T katG 0.002
4199 Sphingosine 1-phosphate receptor Edg-8 S1PR5 0.002
106 Cannabinoid receptor 2 CNR2 0.002
439 Glutamate [NMDA] receptor subunit epsilon-4 GRIN2D 0.0019
3932 Glutathione S-transferase A2 GSTA2 0.0019
6174 50S ribosomal protein L32 rpmF 0.0019
2499 Tubulin beta-2C chain TUBB2C 0.0019
4122 Histone deacetylase 2 HDAC2 0.0019
1196 Complement decay-accelerating factor CD55 0.0019
477 DNA topoisomerase 4 subunit A parC 0.0019
886 DNA topoisomerase 4 subunit A parC 0.0019
6226 DNA topoisomerase 4 subunit A parC 0.0019
251 Alcohol dehydrogenase 1A ADH1A 0.0018
404 DNA gyrase subunit A gyrA 0.0018
6224 DNA gyrase subunit A gyrA 0.0018
1253 Interferon gamma IFNG 0.0018
563 Thyroid peroxidase TPO 0.0018
904 Glutathione S-transferase P GSTP1 0.0018
1457 Long-chain-fatty-acid--CoA ligase 4 ACSL4 0.0018
66 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II HSD3B2 0.0018
5998 Toll-like receptor 8 TLR8 0.0018
4238 50S ribosomal protein L4 rplD 0.0018
5578 50S ribosomal protein L4 rplD 0.0018
6173 50S ribosomal protein L4 rplD 0.0018
6219 50S ribosomal protein L4 rplD 0.0018
712 Tubulin alpha chain TUB1 0.0018
1968 ATP-sensitive inward rectifier potassium channel 12 KCNJ12 0.0018
565 Extracellular calcium-sensing receptor CASR 0.0018
482 Glycine receptor subunit alpha-1 GLRA1 0.0018
683 Potassium transporter GK0582 0.0018
4486 Phenol 2-hydroxylase component B pheA2 0.0018
4477 Dihydrolipoyl dehydrogenase lpdV 0.0018
5077 Dihydrolipoyl dehydrogenase Not Available 0.0018
5117 Dihydrolipoyl dehydrogenase lpd 0.0018
4439 Ferredoxin reductase bphA4 0.0018
5078 Amine oxidase, flavin-containing PSPTO1126 0.0018
526 Thioredoxin reductase trxB 0.0018
3767 Thioredoxin reductase trxB 0.0018
5122 Mersacidin decarboxylase mrsD 0.0017
5095 Putidaredoxin reductase camA 0.0017
5107 Alkyl hydroperoxide reductase subunit F ahpF 0.0017
5118 Alkyl hydroperoxide reductase subunit F ahpF 0.0017
5114 Putative acyl-CoA dehydrogenase TT_C0779 0.0017
5109 Outer membrane protein p64k or PM-6 m-6 0.0017
5115 FkbI fkbI 0.0017
3133 UDP-galactopyranose mutase glf 0.0017
5099 UDP-galactopyranose mutase glf 0.0017
5097 PROBABLE DIHYDROLIPOAMIDE DEHYDROGENASE LPDA lpdA 0.0017
3763 5,10-methylenetetrahydrofolate reductase metF 0.0017
3918 5,10-methylenetetrahydrofolate reductase MTHFR 0.0017
5094 5,10-methylenetetrahydrofolate reductase metF 0.0017
5102 4-cresol dehydrogenase [hydroxylating] flavoprotein subunit pchF 0.0017
5111 Phenylacetone monooxygenase pamO 0.0017
1329 Apoptosis-inducing factor 1, mitochondrial AIFM1 0.0017
5083 Cryptochrome DASH cry 0.0017
5100 Gamma-aminobutyrate metabolism dehydratase/isomerase abfD 0.0017
5081 L-aspartate oxidase nadB 0.0017
1410 Oxidoreductase HSD17B6 0.0017
4725 Oxidoreductase Not Available 0.0017
5124 Oxidoreductase Not Available 0.0017
5112 Benzoate 1,2-dioxygenase electron transfer component benC 0.0017
67 Prolyl 4-hydroxylase subunit alpha-1 P4HA1 0.0017
613 Atrial natriuretic peptide receptor A NPR1 0.0017
401 Glutamate [NMDA] receptor subunit zeta-1 GRIN1 0.0017
650 Aldo-keto reductase family 1 member C3 AKR1C3 0.0017
621 Periplasmic [Fe] hydrogenase 1 Not Available 0.0017
543 Penicillin-binding protein 1B mrcB 0.0017
6186 Penicillin-binding protein 1B ponB 0.0017
6822 Penicillin-binding protein 1b pbp1b 0.0017
6844 Penicillin-binding protein 1b pbp1b 0.0017
514 Potassium voltage-gated channel subfamily H member 6 KCNH6 0.0017
772 Potassium voltage-gated channel subfamily H member 7 KCNH7 0.0017
139 Aldo-keto reductase family 1 member C1 AKR1C1 0.0017
5878 Alpha-7 nicotinic cholinergic receptor subunit CHRFAM7A 0.0017
1050 Bile salt sulfotransferase SULT2A1 0.0017
159 Penicillin-binding protein 2B penA 0.0017
6121 Penicillin-binding protein 2B penA 0.0017
2808 Chloramphenicol acetyltransferase 3 cat3 0.0016
3610 Thioredoxin reductase 1, cytoplasmic TXNRD1 0.0016
444 Alcohol dehydrogenase 1B ADH1B 0.0016
94 5-hydroxytryptamine 4 receptor HTR4 0.0016
714 Glutathione reductase, mitochondrial GSR 0.0016
102 DNA topoisomerase I, mitochondrial TOP1MT 0.0016
3102 Flavohemoprotein hmp 0.0016
4969 Flavohemoprotein hmp 0.0016
515 26S proteasome non-ATPase regulatory subunit 1 PSMD1 0.0016
522 26S proteasome non-ATPase regulatory subunit 2 PSMD2 0.0016
1852 Microtubule-associated protein 2 MAP2 0.0016
5787 Angiopoietin-1 receptor TEK 0.0016
173 Toll-like receptor 7 TLR7 0.0016
3854 Basic fibroblast growth factor receptor 1 FGFR1 0.0016
6206 DNA-directed RNA polymerase subunit beta' rpoC 0.0016
6154 Multidrug and toxin extrusion protein 1 SLC47A1 0.0016
3233 Bile acid receptor NR1H4 0.0015
4440 NADH peroxidase npr 0.0015
5091 UDP-N-acetylenolpyruvoylglucosamine reductase murB 0.0015
5093 UDP-N-acetylenolpyruvoylglucosamine reductase murB 0.0015
3594 Deoxyribodipyrimidine photo-lyase phr 0.0015
5079 Deoxyribodipyrimidine photo-lyase phrB 0.0015
5080 Deoxyribodipyrimidine photo-lyase phr 0.0015
76 Nitric-oxide synthase, brain NOS1 0.0015
5072 N,N-dimethylglycine oxidase dmg 0.0015
473 L-lactate dehydrogenase A chain LDHA 0.0015
2470 Pyruvate oxidase pox5 0.0015
5073 Ferredoxin--NADP reductase petH 0.0015
5076 Ferredoxin--NADP reductase fpr 0.0015
5119 Ferredoxin--NADP reductase petH 0.0015
5121 Ferredoxin--NADP reductase fpr 0.0015
5075 Sulfite reductase [NADPH] flavoprotein alpha-component cysJ 0.0015
6138 Multidrug resistance protein 3 ABCB4 0.0015
709 ATP-sensitive inward rectifier potassium channel 1 KCNJ1 0.0015
182 2-oxoglutarate dehydrogenase E1 component, mitochondrial OGDH 0.0015
440 Isovaleryl-CoA dehydrogenase, mitochondrial IVD 0.0015
667 Acyl-CoA dehydrogenase family member 8, mitochondrial ACAD8 0.0015
3506 Glutaryl-CoA dehydrogenase, mitochondrial GCDH 0.0015
5003 Acyl-CoA dehydrogenase, short-chain specific Not Available 0.0015
2526 NADPH-ferredoxin reductase fprA fprA 0.0015
6639 Peroxisomal acyl-coenzyme A oxidase 1 ACOX1 0.0015
3601 Dihydropteroate synthase 1 folP1 0.0015
3807 Dihydropteroate synthase 1 folP1 0.0015
3808 Dihydropteroate synthase 2 folP2 0.0015
3247 2-oxopropyl-CoM reductase, carboxylating xecC 0.0015
2417 Chloramphenicol acetyltransferase cat 0.0015
3278 Chloramphenicol acetyltransferase cat 0.0015
2810 Dr hemagglutinin structural subunit draA 0.0015
1629 Transcription factor AP-1 JUN 0.0015
6689 TraN protein traN 0.0015
6672 Destrin DSTN 0.0015
6680 Cofilin-1 CFL1 0.0015
6670 Ig kappa chain V-I region Bi Not Available 0.0015
6671 Ig heavy chain V-III region VH26 Not Available 0.0015
6688 TraF protein traF 0.0015
6404 Rhomboid protease glpG glpG 0.0015
6797 Rhomboid protease glpG glpG 0.0015
3710 Acyl-CoA thioesterase 2 tesB 0.0015
6685 Outer membrane protein II porB 0.0015
6690 BenF-like porin PFL_1329 0.0015
6681 Probable N-acetylneuraminic acid outer membrane channel protein nanC nanC 0.0015
6687 TraO protein traO 0.0015
5793 Cytochrome c oxidase subunit 2 MT-CO2 0.0015
6559 Cytochrome c oxidase subunit 2 ctaC 0.0015
6669 Cytochrome c oxidase subunit 2 ctaC 0.0015
6668 Cytochrome c oxidase subunit 1-beta ctaDII 0.0015
6679 Colicin-Ia cia 0.0015
6676 Fe(3+)-pyochelin receptor fptA 0.0015
115 Penicillin-binding protein 2 mrdA 0.0015
6069 Penicillin-binding protein 2 mrdA 0.0015
6118 Penicillin-binding protein 2 penA 0.0015
6187 Penicillin-binding protein 2 pbpA 0.0015
6686 Penicillin-binding protein 2 pbp2 0.0015
6939 Penicillin-binding protein 2 mrdA 0.0015
7163 Penicillin-binding protein 2 pbpA 0.0015
6674 Nuclear factor erythroid 2-related factor 1 NFE2L1 0.0015
2718 Chloramphenicol 3-O phosphotransferase Not Available 0.0015
6179 UDP-glucuronosyltransferase 2B17 UGT2B17 0.0015
559 NADH-ubiquinone oxidoreductase chain 1 MT-ND1 0.0015
327 Glutathione reductase gor 0.0015
5110 Glutathione reductase GR2 0.0015
1541 Metalloproteinase mmp20 0.0014
126 D-lactate dehydrogenase dld 0.0014
3545 D-lactate dehydrogenase Not Available 0.0014
4510 D-lactate dehydrogenase ldhA 0.0014
517 Alcohol dehydrogenase 1C ADH1C 0.0014
165 FL cytokine receptor FLT3 0.0014
3185 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial ACADM 0.0014
3254 Bifunctional protein putA [Includes: Proline dehydrogenase putA 0.0014
65 Matrix metalloproteinase-9 Not Available 0.0014
2893 Glycine oxidase thiO 0.0014
6085 Fatty acid-binding protein, intestinal FABP2 0.0014
505 Glutamate [NMDA] receptor subunit epsilon-3 GRIN2C 0.0014
217 Estradiol 17-beta-dehydrogenase 1 HSD17B1 0.0014
2300 Lysozyme E 0.0014
3633 Lysozyme R 0.0014
5597 Lysozyme 17 0.0014
1992 Vitamin D-binding protein GC 0.0013
3573 2,4-dienoyl-CoA reductase [NADPH] fadH 0.0013
319 Opioid receptor, sigma 1 OPRS1 0.0013
2567 Thymidylate synthase thyX thyX 0.0013
1353 DNA topoisomerase 1 TOP1 0.0013
3552 DNA topoisomerase 1 topA 0.0013
2823 Trypanothione reductase TPR 0.0013
2769 P-hydroxybenzoate hydroxylase pobA 0.0013
2809 P-hydroxybenzoate hydroxylase pobA 0.0013
170 Succinate semialdehyde dehydrogenase, mitochondrial ALDH5A1 0.0013
368 Enoyl-[acyl-carrier-protein] reductase [NADH] inhA 0.0013
3228 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0013
3678 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0013
6856 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0013
4760 Mll3241 protein mll3241 0.0013
3395 Iron(III) dicitrate transport protein fecA fecA 0.0013
6385 H subunit of photosynthetic reaction center complex puhA 0.0013
6474 Outer membrane protein W ompW 0.0013
6678 Colicin I receptor cirA 0.0013
3578 Protein crcA crcA 0.0013
6675 Colicin-E3 ceaC 0.0013
2925 Long-chain fatty acid transport protein fadL 0.0013
6480 Outer membrane usher protein papC papC 0.0013
6438 Outer membrane protein G ompG 0.0013
2447 Ammonia channel amtB 0.0013
976 Platelet glycoprotein IX GP9 0.0013
1630 Integrin beta-2 ITGB2 0.0013
6116 Gastric triacylglycerol lipase LIPF 0.0012
4103 Proteasome subunit beta type 2 PSMB2 0.0012
4102 Proteasome subunit beta type 5 PSMB5 0.0012
4101 Proteasome subunit beta type 1 PSMB1 0.0012
780 Retinoic acid receptor RXR-gamma RXRG 0.0012
16 Adenosine A1 receptor ADORA1 0.0012
6153 Solute carrier organic anion transporter family member 4A1 SLCO4A1 0.0012
3806 cGMP-dependent 3',5'-cyclic phosphodiesterase PDE2A 0.0012
3823 Cytokine receptor common gamma chain IL2RG 0.0012
2107 Microtubule-associated protein 1A MAP1A 0.0012
2380 Monomeric sarcosine oxidase soxA 0.0012
4217 Telomerase reverse transcriptase TERT 0.0012
6645 D-amino-acid oxidase DAO 0.0012
6428 Light-harvesting protein B-800/850 beta chain Not Available 0.0012
6427 Light-harvesting protein B-800/850 alpha chain Not Available 0.0012
6533 Light-harvesting protein B-800/850 alpha chain A1 0.0012
200 Carnitine O-palmitoyltransferase 2, mitochondrial CPT2 0.0012
451 Carnitine O-palmitoyltransferase I, liver isoform CPT1A 0.0012
1295 Fatty acid synthase FASN 0.0012
6524 Protein tonB tonB 0.0012
2679 Vitamin B12 transporter btuB btuB 0.0012
810 Heme oxygenase 1 HMOX1 0.0012
3391 Heme oxygenase 1 pbsA1 0.0012
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.0012
6146 High affinity copper uptake protein 1 SLC31A1 0.0012
1178 Adenosine A2a receptor ADORA2A 0.0011
5251 Carbonyl reductase [NADPH] 1 CBR1 0.0011
469 Annexin A1 ANXA1 0.0011
88 Retinoic acid receptor RXR-beta RXRB 0.0011
6677 Myelin P2 protein PMP2 0.0011
754 Pancreatic triacylglycerol lipase PNLIP 0.0011
174 Sigma 1-type opioid receptor SIGMAR1 0.0011
569 Retinal dehydrogenase 2 ALDH1A2 0.0011
951 Macrophage colony-stimulating factor 1 receptor CSF1R 0.0011
1971 cAMP-specific 3',5'-cyclic phosphodiesterase 4A PDE4A 0.0011
1302 Dihydropyrimidine dehydrogenase [NADP+] DPYD 0.0011
579 Alcohol dehydrogenase class 4 mu/sigma chain ADH7 0.0011
792 Aldehyde dehydrogenase, dimeric NADP-preferring ALDH3A1 0.0011
816 Biliverdin reductase A BLVRA 0.0011
316 4-trimethylaminobutyraldehyde dehydrogenase ALDH9A1 0.0011
936 Ephrin type-A receptor 2 EPHA2 0.0011
724 Interleukin-2 receptor alpha chain IL2RA 0.0011
717 Interleukin-2 receptor subunit beta IL2RB 0.0011
3809 Estrogen-related receptor gamma ESRRG 0.0011
820 Glycine receptor subunit alpha-2 GLRA2 0.0011
337 NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial NDUFS7 0.001
214 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial NDUFS3 0.001
803 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial NDUFS2 0.001
7 Nitric oxide synthase, inducible NOS2 0.001
1810 Protein S100-A1 S100A1 0.001
6097 Protein S100-A2 S100A2 0.001
4203 Histamine N-methyltransferase HNMT 0.001
4116 Dihydropteroate synthetase Not Available 0.001
4228 Keratin, type II cytoskeletal 7 KRT7 0.001
611 Retinal dehydrogenase 1 ALDH1A1 0.001
6044 Serum paraoxonase/lactonase 3 PON3 0.001
1144 Hepatocyte growth factor receptor MET 0.001
84 Nuclear receptor 0B1 NR0B1 0.001
493 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial CYP27B1 0.001
695 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A PDE10A 0.001
164 Histamine H4 receptor HRH4 0.001
1192 Sulfotransferase 1A1 SULT1A1 0.001
512 DNA-directed RNA polymerase alpha chain rpoA 0.001
5772 DNA-directed RNA polymerase alpha chain rpoA 0.001
838 Inosine-5'-monophosphate dehydrogenase 1 IMPDH1 0.001
4041 Microsomal glutathione S-transferase 2 MGST2 0.001
6861 Alcohol dehydrogenase [NADP+] AKR1A1 0.001
796 Inosine-5'-monophosphate dehydrogenase 2 IMPDH2 0.001
6824 Tyrosine-protein kinase Lyn LYN 0.001
241 Calcium-transporting ATPase type 2C member 1 ATP2C1 0.001
6352 Reaction center protein H chain puhA 0.001
6456 Reaction center protein H chain puhA 0.001
6682 Reaction center protein H chain puhA 0.001
6353 Reaction center protein L chain pufL 0.001
6454 Reaction center protein L chain pufL 0.001
6683 Reaction center protein L chain pufL 0.001
6354 Reaction center protein M chain pufM 0.001
6455 Reaction center protein M chain pufM 0.001
6684 Reaction center protein M chain pufM 0.001
6351 Photosynthetic reaction center cytochrome c subunit pufC 0.001
3961 G protein-activated inward rectifier potassium channel 4 KCNJ5 0.001
353 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2 NDUFA4L2 0.001
374 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1 NDUFB1 0.001
598 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11 NDUFA11 0.001
247 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1 NDUFA1 0.001
190 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 NDUFA4 0.001
755 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 NDUFA3 0.001
582 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 NDUFA13 0.001
343 NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial NDUFC1 0.001
300 NADH-ubiquinone oxidoreductase chain 4L MT-ND4L 0.001
475 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial NDUFB2 0.001
99 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 NDUFS5 0.001
384 NADH-ubiquinone oxidoreductase chain 6 MT-ND6 0.001
656 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 NDUFB9 0.001
525 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 NDUFA5 0.001
219 NADH-ubiquinone oxidoreductase chain 3 MT-ND3 0.001
104 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial NDUFS6 0.001
236 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 NDUFA6 0.001
417 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 NDUFB6 0.001
324 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 NDUFB4 0.001
568 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 NDUFB7 0.001
829 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 NDUFA12 0.001
602 Acyl carrier protein, mitochondrial NDUFAB1 0.001
272 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 NDUFB10 0.001
313 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 NDUFB3 0.001
607 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 NDUFA2 0.001
555 NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial NDUFS4 0.001
746 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial NDUFB8 0.001
270 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial NDUFB5 0.001
30 NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial NDUFV3 0.001
446 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 NDUFA7 0.001
41 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial NDUFS8 0.001
326 L-lactate dehydrogenase A-like 6A LDHAL6A 0.001
149 Alpha-aminoadipic semialdehyde dehydrogenase ALDH7A1 0.001
112 L-lactate dehydrogenase A-like 6B LDHAL6B 0.001
671 Pyruvate dehydrogenase E1 component alpha subunit, testis-specific form, mitochondrial PDHA2 0.001
152 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial NDUFV2 0.001
609 15-hydroxyprostaglandin dehydrogenase [NAD+] HPGD 0.001
107 C-4 methylsterol oxidase SC4MOL 0.001
608 NADH-ubiquinone oxidoreductase chain 4 MT-ND4 0.001
405 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 NDUFA8 0.001
372 Estradiol 17-beta-dehydrogenase 3 HSD17B3 0.001
662 Fatty aldehyde dehydrogenase ALDH3A2 0.001
644 Heme oxygenase 2 HMOX2 0.001
4982 Heme oxygenase 2 pbsA2 0.001
729 GDP-L-fucose synthetase TSTA3 0.001
3463 GDP-L-fucose synthetase fcl 0.001
487 Aldo-keto reductase family 1 member C4 AKR1C4 0.001
167 L-lactate dehydrogenase C chain LDHC 0.001
141 3-hydroxyisobutyrate dehydrogenase, mitochondrial HIBADH 0.001
206 3-keto-steroid reductase HSD17B7 0.001
196 D-beta-hydroxybutyrate dehydrogenase, mitochondrial BDH1 0.001
721 NADH-ubiquinone oxidoreductase chain 2 MT-ND2 0.001
231 Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic GPD1 0.001
91 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial NDUFA10 0.001
14 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial IDH3A 0.001
50 Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating NSDHL 0.001
335 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial NDUFA9 0.001
216 Aldehyde dehydrogenase 3B2 ALDH3B2 0.001
616 Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial IDH3B 0.001
637 NADH-ubiquinone oxidoreductase chain 5 MT-ND5 0.001
9 Estradiol 17-beta-dehydrogenase 2 HSD17B2 0.001
628 Pyruvate dehydrogenase E1 component alpha subunit, somatic form, mitochondrial PDHA1 0.001
848 Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial IDH3G 0.001
145 Corticosteroid 11-beta-dehydrogenase isozyme 2 HSD11B2 0.001
643 Peroxisomal bifunctional enzyme EHHADH 0.001
539 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial NDUFV1 0.001
496 Aldehyde dehydrogenase 3B1 ALDH3B1 0.001
34 7-dehydrocholesterol reductase DHCR7 0.001
288 Trifunctional enzyme subunit alpha, mitochondrial HADHA 0.001
711 UDP-glucose 6-dehydrogenase UGDH 0.001
3672 UDP-glucose 6-dehydrogenase hasB 0.001
531 Aldehyde dehydrogenase X, mitochondrial ALDH1B1 0.001
180 D-3-phosphoglycerate dehydrogenase PHGDH 0.001
3726 D-3-phosphoglycerate dehydrogenase serA 0.001
4291 D-3-phosphoglycerate dehydrogenase serA 0.001
258 Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial ALDH6A1 0.001
271 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial ALDH4A1 0.001
393 GDH/6PGL endoplasmic bifunctional protein [Includes: Glucose 1-dehydrogenase H6PD 0.001
548 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial NDUFS1 0.001
3868 Calcineurin subunit B isoform 2 PPP3R2 0.001
421 Calcium signal-modulating cyclophilin ligand CAMLG 0.001
572 Integrin alpha-L ITGAL 0.0009
5798 Mitogen-activated protein kinase 11 MAPK11 0.0009
2828 Squalene--hopene cyclase shc 0.0009
4773 Deoxycytidine kinase DCK 0.0009
2320 Thymidine kinase, cytosolic TK1 0.0009
267 Plasminogen activator inhibitor 1 SERPINE1 0.0009
3830 Calreticulin CALR 0.0009
537 ATP synthase delta chain, mitochondrial ATP5D 0.0009
1864 RET proto-oncogene RET 0.0009
646 Malate dehydrogenase, cytoplasmic MDH1 0.0009
6105 3-oxo-5-beta-steroid 4-dehydrogenase AKR1D1 0.0009
350 3-hydroxyacyl-CoA dehydrogenase type-2 HSD17B10 0.0009
1950 Epithelial discoidin domain-containing receptor 1 DDR1 0.0009
3086 Plasmepsin-2 Not Available 0.0009
6170 ATP-binding cassette sub-family A member 3 ABCA3 0.0009
6094 BCR/ABL fusion protein isoform X9 BCR/ABL fusion 0.0009
454 Peroxisomal multifunctional enzyme type 2 HSD17B4 0.0009
459 Retinoic acid receptor RXR-alpha RXRA 0.0009
328 Sorbitol dehydrogenase SORD 0.0009
6149 Solute carrier family 22 member 10 SLC22A10 0.0009
363 NADP-dependent malic enzyme, mitochondrial ME3 0.0009
1048 Protein S100-A13 S100A13 0.0009
597 Dihydropteridine reductase QDPR 0.0009
2226 Protein S100-A12 S100A12 0.0009
396 Alcohol dehydrogenase 4 ADH4 0.0009
1759 85 kDa calcium-independent phospholipase A2 PLA2G6 0.0009
1770 Phospholipase C PLCL1 0.0009
2841 Phospholipase C plc 0.0009
1648 Elastin ELN 0.0009
830 Glutamate dehydrogenase 2, mitochondrial GLUD2 0.0009
2283 Steroid Delta-isomerase ksi 0.0009
2920 Steroid Delta-isomerase ksi 0.0009
208 DNA-directed RNA polymerase beta' chain rpoC 0.0009
5774 DNA-directed RNA polymerase beta' chain rpoC 0.0009
6931 Calcium-activated potassium channel subunit beta-1 KCNMB1 0.0009
6932 Calcium-activated potassium channel subunit beta-3 KCNMB3 0.0009
390 Adenosine A3 receptor ADORA3 0.0009
6933 Calcium-activated potassium channel subunit beta-4 KCNMB4 0.0009
6934 Small conductance calcium-activated potassium channel protein 1 KCNN1 0.0009
6935 Small conductance calcium-activated potassium channel protein 2 KCNN2 0.0009
6936 Small conductance calcium-activated potassium channel protein 3 KCNN3 0.0009
6034 Hydroxyindole O-methyltransferase ASMT 0.0009
6035 Nuclear receptor ROR-beta RORB 0.0009
6036 Eosinophil peroxidase EPX 0.0009
6169 ATP-binding cassette sub-family A member 5 ABCA5 0.0009
2132 Protein S100-B S100B 0.0009
635 Estradiol 17-beta-dehydrogenase 8 HSD17B8 0.0009
666 NADP-dependent malic enzyme ME1 0.0009
3404 Exotoxin A eta 0.0008
6026 Alcohol dehydrogenase 6 ADH6 0.0008
6218 Pannexin-1 PANX1 0.0008
296 Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial MTHFD2 0.0008
419 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial HADH 0.0008
6221 Steroid hormone receptor ERR1 ESRRA 0.0008
22 30S ribosomal protein S4 rpsD 0.0008
6714 30S ribosomal protein S4 rpsD 0.0008
5934 Cytochrome P450 26A1 CYP26A1 0.0008
857 Malate dehydrogenase, mitochondrial MDH2 0.0008
4037 Hypothetical protein GPX1 0.0008
4297 Hypothetical protein SP_1951 0.0008
4521 Hypothetical protein BC_2969 0.0008
4540 Hypothetical protein TM_1070 0.0008
4555 Hypothetical protein MT1739 0.0008
4569 Hypothetical protein mshD 0.0008
4578 Hypothetical protein PA3270 0.0008
4747 Hypothetical protein PA3967 0.0008
5177 Hypothetical protein TM_0096 0.0008
5194 Hypothetical protein PA1204 0.0008
5240 Hypothetical protein Rv2991 0.0008
5370 Hypothetical protein TM_1158 0.0008
5710 Hypothetical protein Tb927.5.1360 0.0008
4527 Putative hydrolase ycdX ycdX 0.0008
4536 Transcriptional regulator, IclR family TM_0065 0.0008
2501 Protein ygbM ygbM 0.0008
4545 Molybdopterin-converting factor subunit 2 moaE 0.0008
77 L-lactate dehydrogenase B chain LDHB 0.0008
4522 Arginine N-succinyltransferase subunit alpha astA 0.0008
4106 Guanylate kinase GUK1 0.0008
4516 Guanylate kinase gmk 0.0008
4538 Hypothetical protein VC1899 VC_1899 0.0008
4529 Oxalate decarboxylase oxdC oxdC 0.0008
4514 Citrate lyase beta subunit-like protein citE 0.0008
4781 Citrate lyase beta subunit-like protein DR_1240 0.0008
4526 Oligopeptide ABC transporter, periplasmic oligopeptide-binding protein TM_1223 0.0008
4524 Mannose-6-phosphate isomerase yvyI 0.0008
4535 Glutaconyl-CoA decarboxylase subunit alpha gcdA 0.0008
4547 Iron binding protein FbpA fbpA 0.0008
4548 Gyrase B gyrB 0.0008
4546 Aminotransferase, putative TM_1131 0.0008
658 Para-aminobenzoate synthase component 1 pabB 0.0008
521 ATP-binding cassette transporter sub-family C member 9 ABCC9 0.0008
4515 Peripheral plasma membrane protein CASK CASK 0.0008
2325 Sulfotransferase family cytosolic 2B member 1 SULT2B1 0.0008
12 Alcohol dehydrogenase class 3 ADH5 0.0008
248 Pyrroline-5-carboxylate reductase 1 PYCR1 0.0008
802 Pyrroline-5-carboxylate reductase 2 PYCR2 0.0008
1039 Histone deacetylase 9 HDAC9 0.0008
626 Cysteine dioxygenase type 1 CDO1 0.0008
110 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial PDHB 0.0008
627 11-cis retinol dehydrogenase RDH5 0.0008
640 Aldehyde dehydrogenase 1A3 ALDH1A3 0.0008
1867 Major prion protein PRNP 0.0008
2232 Interleukin-5 IL5 0.0008
11 NAD(P) transhydrogenase, mitochondrial NNT 0.0008
424 Dihydroorotate dehydrogenase, mitochondrial DHODH 0.0008
1593 Mucin-2 MUC2 0.0008
4031 Glutathione S-transferase A1 GSTA1 0.0008
599 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 0.0008
4426 Glyceraldehyde-3-phosphate dehydrogenase gap 0.0008
4454 Glyceraldehyde-3-phosphate dehydrogenase gap 0.0008
4489 Glyceraldehyde-3-phosphate dehydrogenase gap 0.0008
201 Glutamate dehydrogenase 1, mitochondrial GLUD1 0.0008
1360 Sphingomyelin phosphodiesterase SMPD1 0.0008
794 Glyceraldehyde-3-phosphate dehydrogenase, testis-specific GAPDHS 0.0008
760 Fibroblast growth factor 1 FGF1 0.0008
13 Aminomethyltransferase, mitochondrial AMT 0.0008
933 Proto-oncogene tyrosine-protein kinase Src SRC 0.0008
1649 Small inducible cytokine A2 CCL2 0.0008
132 ATP-binding cassette sub-family A member 1 ABCA1 0.0008
74 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial DLAT 0.0008
3856 Fibroblast growth factor receptor 3 FGFR3 0.0008
5463 Calcium-activated potassium channel subunit beta 2 KCNMB2 0.0008
5766 NAD-dependent deacetylase sirtuin-5 SIRT5 0.0008
2091 Endoplasmin HSP90B1 0.0008
4496 C-terminal-binding protein 1 CTBP1 0.0008
6893 Calcium/calmodulin-dependent protein kinase type II gamma chain CAMK2G 0.0007
765 Indoleamine 2,3-dioxygenase IDO1 0.0007
896 Glutathione S-transferase Mu 1 GSTM1 0.0007
461 Glycine receptor subunit alpha-3 GLRA3 0.0007
1524 Peptidyl-prolyl cis-trans isomerase A PPIA 0.0007
6700 Peptidyl-prolyl cis-trans isomerase A ppiA 0.0007
57 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type I HSD3B1 0.0007
130 Prostacyclin synthase PTGIS 0.0007
83 Alpha-aminoadipic semialdehyde synthase, mitochondrial AASS 0.0007
6103 Arylamine N-acetyltransferase 1 NAT1 0.0007
4517 Probable butyrate kinase 2 buk2 0.0007
3261 Signal recognition particle protein ffh 0.0007
4528 Phenazine biosynthesis protein PhzD phzD1 0.0007
4533 Glyoxalase family protein BC_1747 0.0007
56 Delta-aminolevulinic acid dehydratase ALAD 0.0007
2356 Delta-aminolevulinic acid dehydratase hemB 0.0007
3613 Delta-aminolevulinic acid dehydratase hemB 0.0007
3674 Delta-aminolevulinic acid dehydratase hemB 0.0007
3759 Glutathione S-transferase gst 0.0007
4541 Glutathione S-transferase GST 0.0007
4542 Glutaminase 1 glsA1 0.0007
4544 Glutaminase 1 glsA1 0.0007
2929 (S)-2-haloacid dehalogenase dhlB 0.0007
2995 (S)-2-haloacid dehalogenase Not Available 0.0007
3237 Beta-lactamase OXA-2 bla 0.0007
4532 Gephyrin GPHN 0.0007
166 NAD-dependent malic enzyme, mitochondrial ME2 0.0007
686 Aldo-keto reductase family 1 member C2 AKR1C2 0.0007
279 Tyrosinase TYR 0.0007
679 C-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 0.0007
591 Glutamate [NMDA] receptor subunit 3B GRIN3B 0.0007
630 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial ACADSB 0.0007
2112 Toll-like receptor 9 TLR9 0.0007
6207 30S ribosomal protein S14 rpsN 0.0007
6209 30S ribosomal protein S19 rpsS 0.0007
6712 30S ribosomal protein S19 rpsS 0.0007
6726 30S ribosomal protein S19 rpsS 0.0007
6100 BDNF/NT-3 growth factors receptor NTRK2 0.0007
645 Penicillin-binding protein 1A mrcA 0.0007
5805 Penicillin-binding protein 1A ponA 0.0007
6185 Penicillin-binding protein 1A mrcA 0.0007
6799 Penicillin-binding protein 1A pbpA 0.0007
5924 Microtubule-associated protein 4 MAP4 0.0007
5923 Microtubule-associated protein tau MAPT 0.0007
2298 Cytochrome P450-cam camC 0.0007
2021 Thrombomodulin THBD 0.0007
2290 ADP-ribosyl cyclase 2 BST1 0.0007
226 Gonadotropin-releasing hormone receptor GNRHR 0.0007
1830 5'-nucleotidase NT5E 0.0007
1502 Peroxisome proliferator-activated receptor delta PPARD 0.0007
125 DNA polymerase beta POLB 0.0007
4531 Putative ketoacyl reductase actIII 0.0007
2775 Dihydroorotate dehydrogenase pyrD 0.0007
3467 Methylglyoxal synthase mgsA 0.0007
3583 6-phosphogluconolactonase pgl 0.0007
6140 Ileal sodium/bile acid cotransporter SLC10A2 0.0007
1123 Eosinophil cationic protein RNASE3 0.0007
2599 Tyrosine-protein kinase HCK HCK 0.0007
144 Hemoglobin subunit alpha HBA1 0.0006
137 FolC bifunctional protein [Includes: Folylpolyglutamate synthase folC 0.0006
2525 3-phosphoshikimate 1-carboxyvinyltransferase aroA 0.0006
3201 3-phosphoshikimate 1-carboxyvinyltransferase aroA 0.0006
890 Niemann-Pick C1-like protein 1 NPC1L1 0.0006
2688 Peptide deformylase def 0.0006
2708 Peptide deformylase def 0.0006
3004 Peptide deformylase def 0.0006
4337 Peptide deformylase def 0.0006
4338 Peptide deformylase def 0.0006
5368 Peptide deformylase def 0.0006
5371 Peptide deformylase def 0.0006
6375 Peptide deformylase def 0.0006
6378 Peptide deformylase def 0.0006
6379 Peptide deformylase def 0.0006
6776 Peptide deformylase def 0.0006
6900 Peptide deformylase def 0.0006
4534 Cytohesin-2 CYTH2 0.0006
3126 Poly [ADP-ribose] polymerase 1 PARP1 0.0006
291 Nitric-oxide synthase, endothelial NOS3 0.0006
4192 DNA topoisomerase 2-beta TOP2B 0.0006
2548 Subtilisin Carlsberg apr 0.0006
6167 Organic solute transporter subunit beta OSTB 0.0006
6166 Organic solute transporter subunit alpha OSTA 0.0006
4269 Hypoxanthine-guanine phosphoribosyltransferase, putative HGPRTase 0.0006
3611 Cytidine deaminase cdd 0.0006
3707 Cytidine deaminase cdd 0.0006
4211 Cytidine deaminase CDA 0.0006
1291 cAMP response element-binding protein CREB1 0.0006
1569 G1/S-specific cyclin-D1 CCND1 0.0006
1525 Heparin-binding growth factor 2 FGF2 0.0006
4210 Toll-like receptor 4 TLR4 0.0005
1341 Histamine H3 receptor HRH3 0.0005
1760 Aminopeptidase N ANPEP 0.0005
6843 Aminopeptidase N pepN 0.0005
1262 Corticotropin-lipotropin POMC 0.0005
117 Sterol O-acyltransferase 1 SOAT1 0.0005
489 Monocarboxylate transporter 2 SLC16A7 0.0005
1939 Heat shock protein HSP 90-alpha HSP90AA1 0.0005
244 Angiotensin-converting enzyme ACE 0.0005
2180 3-phosphoinositide-dependent protein kinase 1 PDPK1 0.0005
6211 Tubulin epsilon chain TUBE1 0.0005
6212 Tubulin gamma-1 chain TUBG1 0.0005
6210 Tubulin delta chain TUBD1 0.0005
822 Aldose reductase AKR1B1 0.0005
6042 Prostaglandin reductase 2 PTGR2 0.0005
3027 Streptavidin Not Available 0.0005
937 Proto-oncogene tyrosine-protein kinase LCK LCK 0.0005
541 cAMP-specific 3',5'-cyclic phosphodiesterase 4B PDE4B 0.0005
500 Monocarboxylate transporter 4 SLC16A3 0.0005
734 D1 dopamine receptor-interacting protein calcyon CALY 0.0005
1714 Mitogen-activated protein kinase 3 MAPK3 0.0005
2038 Inhibitor of nuclear factor kappa-B kinase subunit beta IKBKB 0.0004
476 RAC-alpha serine/threonine-protein kinase AKT1 0.0004
5682 Ribonuclease pancreatic RNASE1 0.0004
1374 Natriuretic peptides B NPPB 0.0004
1827 Gap junction alpha-1 protein GJA1 0.0004
1908 Vascular cell adhesion protein 1 VCAM1 0.0004
2450 Tyrosine-protein kinase ITK/TSK ITK 0.0004
935 Proto-oncogene tyrosine-protein kinase Yes YES1 0.0004
1063 Signal transducer and activator of transcription 5B STAT5B 0.0004
2216 Fibroblast growth factor receptor 4 FGFR4 0.0004
1176 Mitogen-activated protein kinase 1 MAPK1 0.0004
1313 Lactoylglutathione lyase GLO1 0.0004
594 Thyroxine-binding globulin SERPINA7 0.0004
934 Proto-oncogene tyrosine-protein kinase Fyn FYN 0.0004
719 Retinoic acid receptor responder protein 1 RARRES1 0.0003
770 Retinoic acid-induced protein 3 GPRC5A 0.0003
268 Adenosine A2b receptor ADORA2B 0.0003
828 Phenylalanine-4-hydroxylase PAH 0.0003
3109 Phenylalanine-4-hydroxylase phhA 0.0003
758 Thyroid hormone receptor alpha THRA 0.0003
484 Tyrosine-protein kinase ABL2 ABL2 0.0003
2240 Cell division protein kinase 2 CDK2 0.0003
199 Monocarboxylate transporter 8 SLC16A2 0.0003
245 Large neutral amino acids transporter small subunit 1 SLC7A5 0.0003
346 Thyroid hormone receptor beta-1 THRB 0.0003
1275 Estrogen sulfotransferase SULT1E1 0.0003
1768 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit GNG2 0.0003
1268 Neuropeptide S receptor NPSR1 0.0003
1571 G protein-activated inward rectifier potassium channel 1 KCNJ3 0.0003
1581 G protein-activated inward rectifier potassium channel 2 KCNJ6 0.0003
564 Cellular retinoic acid-binding protein 1 CRABP1 0.0003
859 Cellular retinoic acid-binding protein 2 CRABP2 0.0003
6172 ATP-binding cassette sub-family B member 8, mitochondrial ABCB8 0.0003
908 Glutathione S-transferase theta-1 GSTT1 0.0003
6073 Potassium channel subfamily K member 9 KCNK9 0.0003
6072 Potassium channel subfamily K member 3 KCNK3 0.0003
3957 Adenosine deaminase ADA 0.0002
6168 Solute carrier family 22 member 16 SLC22A16 0.0002
162 Retinoic acid receptor gamma-1 RARG 0.0002
4936 Cytochrome c2 iso-2 Not Available 0.0001
4916 Cyanoglobin glbN 0.0001
4994 Hemoglobin-like protein HbO glbO 0.0001
4915 Cytochrome c-550 psbV 0.0001
4959 Cytochrome c-550 psbV 0.0001
5216 Cytochrome c-550 psbV 0.0001
4925 Cytochrome c-type protein SHP shp 0.0001
4904 Cytochrome c family protein GSU1996 0.0001
4943 Cytochrome c6 petJ 0.0001
3116 Bacterioferritin bfr 0.0001
4906 Bacterioferritin bfr 0.0001
4965 Bacterioferritin bfr 0.0001
4954 Soluble cytochrome b558 Not Available 0.0001
4934 Cytochrome c-551 nirM 0.0001
5218 Cytochrome c-551 nirM 0.0001
4905 Cytochrome c2 Not Available 0.0001
4939 Cytochrome c2 cycA 0.0001
4964 Cytochrome c2 cycA 0.0001
4979 Cytochrome c2 cycA 0.0001
6673 Cytochrome c2 cycA 0.0001
4910 Cytoglobin CYGB 0.0001
4984 Neuroglobin NGB 0.0001
4981 Iron-starvation protein PigA pigA 0.0001
4909 CooA protein cooA 0.0001
4998 Hemoglobin-like protein yjbI yjbI 0.0001
4935 Cytochrome c-554 cycA1 0.0001
4947 Bacterial hemoglobin vhb 0.0001
4975 Cytochrome c-556 RPA3973 0.0001
4942 Diheme cytochrome c napB napB 0.0001
4931 Cytochrome P450 167A1 CYP167A1 0.0001
5000 HemO hemO 0.0001
4972 P450cin cinA 0.0001
4960 Putative cytochrome P450-family protein SCO7417 0.0001
4971 Nonaheme cytochrome c hmcA 0.0001
4989 Cytochrome c551 peroxidase ccp 0.0001
5222 Cytochrome c551 peroxidase ccpA 0.0001
4961 Hemophore HasA hasA 0.0001
4976 Apocytochrome f petA 0.0001
6407 Apocytochrome f petA 0.0001
4907 Cytochrome c-L moxG 0.0001
6865 Cytochrome c-L moxG 0.0001
4993 Hydroxylamine oxidoreductase hao1 0.0001
4764 Cytochrome P450 165C4 CYP165C4 0.0001
4926 Heme-based aerotactic transducer hemAT hemAT 0.0001
4952 Catalase/peroxidase katA 0.0001
4970 Cytochrome c nitrite reductase catalytic subunit nrfA 0.0001
4937 Cytochrome oxidase subunit II rcoxA 0.0001
4903 Methyl-accepting chemotaxis protein Tar4 0.0001
4999 Cytochrome P450 165B3 CYP165B3 0.0001
3093 Catalase HPII katE 0.0001
4908 Heme-regulated cyclic AMP phosphodiesterase dosP 0.0001
4922 Cytochrome c, putative SO_4144 0.0001
4920 Peroxidase/catalase katG 0.0001
4990 PpcA ppcA 0.0001
4948 Cytochrome c-553 Not Available 0.0001
4923 Cytochrome c3 DvMF_2499 0.0001
4945 Cytochrome c3 Not Available 0.0001
4949 Cytochrome c3 DVU_3171 0.0001
4968 Cytochrome c3 cytc3 0.0001
4997 Cytochrome c3 SO_2727 0.0001
5219 Cytochrome c3 cyd 0.0001
2119 Cytochrome b5 CYB5A 0.0001
4902 Nine-heme cytochrome c Ddes_2038 0.0001
3189 High-molecular-weight cytochrome c hmcA 0.0001
4956 Quinohemoprotein alcohol dehydrogenase ADH IIB qbdA 0.0001
3375 Acidic cytochrome c3 Not Available 0.0001
4988 Sulfite oxidase, mitochondrial SUOX 0.0001
2915 Sensor protein fixL fixL 0.0001
4944 Sensor protein fixL fixL 0.0001
4813 Heme oxygenase hmuO 0.0001
5769 Heme oxygenase Not Available 0.0001
3570 Cytochrome P450 152A1 cypC 0.0001
4385 Cytochrome c' Not Available 0.0001
4967 Cytochrome c' cycA 0.0001
5038 Cytochrome c' Not Available 0.0001
5223 Cytochrome c' cycP 0.0001
4289 Cytochrome P450 TT_P0059 0.0001
6262 Cytochrome P450 staP 0.0001
4992 Cytochrome c peroxidase Not Available 0.0001
2230 Catalase CAT 0.0001
3249 Catalase katA 0.0001
3625 Catalase katA 0.0001
4539 Catalase katA 0.0001
4941 Catalase katB 0.0001
3670 Soluble cytochrome b562 precursor cybC 0.0001
3411 Cytochrome P450 121 cyp121 0.0001
3291 Cytochrome c-552 cycA 0.0001
4927 Cytochrome c-552 nrfA 0.0001
4938 Cytochrome c-552 cycA 0.0001
4953 Cytochrome c-552 nrfA 0.0001
5217 Cytochrome c-552 cycM 0.0001
2617 Nitric oxide synthase oxygenase nos 0.0001
2701 Nitric oxide synthase oxygenase nos 0.0001
4386 Hemoglobin-like protein HbN glbN 0.0001
3127 Nitrite reductase nirS 0.0001
3284 Nitrite reductase nirS 0.0001
2845 Bifunctional P-450:NADPH-P450 reductase CYP102A1 0.0001
2972 6-deoxyerythronolide B hydroxylase eryF 0.0001
3221 Cytochrome c4 cc4 0.0001
4608 Putative cytochrome P450 SCO1207 0.0001
4963 Putative cytochrome P450 SCO2884 0.0001
6254 Putative cytochrome P450 SCO6998 0.0001
358 Cystathionine beta-synthase CBS 0
1507 Cytochrome c CYCS 0
693 Hemoglobin subunit beta HBB 0
6268 Hydroxyacid oxidase 1 HAO1 0
↑